Consejo Nacional de Salud

324
Cochrane Database of Systematic Reviews
2008, Issue 1. Art. No.: CD002898. DOI:
10.1002/14651858.CD002898.pub3
114 Hodson EM, Craig JC, Strippoli GFM, Webster
AC. Antiviral medications for preventing
cytomegalovirus disease in solid organ
transplant recipients. Cochrane Database of
Systematic Reviews 2008, Issue 2. Art. No.:
CD003774. DOI: 10.1002/14651858.
CD003774.pub3.
115 Podzamczer D,King M, Klein C,Flexner
C,Katlama F,Havlir D,Letendre S, Eron J,
Brun S, Bernstein B, High-Dose Lopinavir/Ritonavir
in Highly Treatment-Experienced
HIV-1 Patients: Efficacy, Safety,
and Predictors of Response, HIV Clin Trials
2007;8(4):193–204, doi: 10.1310/
hct0804-193
116 Sprinz E, Neto A, Bargman E, Green S,
Lou M, Sylte J, McMilla F, King K, Rode R,
Brun S, Hanna G, Podsadecki T, Substitution
with Lopinavir/Ritonavir Improves
Patient-Reported Outcomes Including Quality
of Life in Patients Who Were Intolerant
to Their Antiretroviral Therapy, HIV Clin
Trials 2006;7(6):291–308, doi: 10.1310/
hct0706-291
117 Riddler S, Haubrich R, DiRienzo G, Peeples
L, Powderly W, Klingman W, Garren K,
George T, Rooney J, Brizz B, Lalloo U, Murphy
L, Swindells S, Havlir D, Mellors W,
Class-Sparing Regimens for Initial Treatment
of HIV-1 Infection. The New England Journal
of Medicine. May 15, 2008 vol. 358 no. 20.
118 Rutherford GW, Sangani PR, Kennedy , GE .
Three- or four- versus two-drug antiretroviral
maintenance regimens for HIV infection.
Cochrane Database of Systematic Reviews
2003, Issue 4. Art. No.: CD002037. DOI:
10.1002/14651858.CD002037
119 Ibid, 97
120 Young TN, Arens FJ, Kennedy GE, Laurie
JW, Rutherford GW. Antiretroviral postexposure
prophylaxis (PEP) for occupational
HIV exposure. Cochrane Database of
Systematic Reviews 2007, Issue 1. Art. No.:
CD002835. DOI: 10.1002/14651858.
CD002835.pub3.
121 Scott M. Hammer; Joseph J. Eron, Jr; Peter
Reiss; et al. Antiretroviral Treatment
of Adult HIV Infection, 2008 Recommendations
of the International, AIDS Society–
USA Panel, , JAMA. 2008;300(5):555-
570 (doi:10.1001/jama.300.5.555),
http://jama.ama-assn.org/cgi/content/
full/300/5/555
122 Barrai-Tran A, Morand-Joubert L, Poizat G,
Raguin G, Le Tiec C, Clavel F, et al, Predictive
Values of the Human Immunodeficiency
Virus Phenotype and Genotype and of Amprenavir
and Lopinavir Inhibitory Quotients
in Heavily Pretreated Patients on a Ritonavir-
Boosted Dual-Protease-Inhibitor Regimen
Antimicrobial Agents And Chemotherapy,
May 2008, p. 1642–1646 Vol. 52, No. 5,
0066-4804/08/$08.00_0 doi:10.1128/
AAC.01314-07.
123 Ibíd., 114
124 Perez, MacArthur R, Walmsley C, Baxter
J, Mullin C, Neaton J, A Randomized Clinical
Trial Comparing Nelfinavir and Ritonavir
in Patients with Advanced HIV Disease
(CPCRA 042/CTN 102). HIV Clin Trials
2004;5(1):7–18
125 Journal Watch From the publishers of The
New England Journal of Medicine, , Seeking
the Best HIV Drugs, June 15, 2008, Vol. 28
No. 12
126 Ibíd., 114